Carlo Pozzilli
Overview
Explore the profile of Carlo Pozzilli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
220
Citations
4915
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barbuti E, Castiello A, Pozzilli V, Carotenuto A, Tomasso I, Moccia M, et al.
Neurotherapeutics
. 2025 Jan;
22(2):e00537.
PMID: 39880749
Ocrelizumab (OCR) and Natalizumab (NTZ) are highly effective treatments widely used in Multiple Sclerosis (MS). However, long-term, real-world comparative data on clinical effectiveness, safety and treatment persistence are limited. This...
2.
Felicetti F, Ruggieri S, Ruotolo I, Livi C, Sellitto G, DAmbrosi G, et al.
Mult Scler Relat Disord
. 2025 Jan;
94:106271.
PMID: 39823692
Objectives: overweight and other cardiovascular risk factors are known contributors to disability accrual in Multiple Sclerosis (MS). We aimed to explore the impact of three hypocaloric dietetic patterns, based on...
3.
Castelli L, Iacovelli C, Loreti C, Fusco A, Riso C, Biscotti L, et al.
J Bodyw Mov Ther
. 2024 Nov;
40:907-913.
PMID: 39593694
Introduction: A range of signs and symptoms that often impair up-per extremity function characterizes Multiple Sclerosis (MS). People with MS may have impairments that make some activities of daily living...
4.
Leodori G, Mancuso M, Maccarrone D, Tartaglia M, Ianniello A, Baione V, et al.
Mult Scler Relat Disord
. 2024 Nov;
92:106146.
PMID: 39504729
Background: Fatigue, depression and slow processing speed are debilitating symptoms in people with Relapsing-Remitting Multiple Sclerosis (RRMS) that significantly impacts on the quality of life. Natalizumab, a disease-modifying treatment, improves...
5.
Petracca M, Ruggieri S, Nistri R, Tomasso I, Barbuti E, Pozzilli V, et al.
Mult Scler
. 2024 Sep;
30(10):1290-1295.
PMID: 39234851
Background: A latent period of variable length elapses between multiple sclerosis (MS) biological onset and the occurrence of the first clinical episode reflecting a central nervous system (CNS) demyelinating event....
6.
Simone M, Lucisano G, Guerra T, Paolicelli D, Rocca M, Morra V, et al.
J Neurol
. 2024 Aug;
271(10):6782-6790.
PMID: 39179712
Background: To compare Expanded Disability Status Scale (EDSS) trajectories over time between Multiple Sclerosis (MS) groups with pediatric (POMS), adult (AOMS) and late (LOMS) onset, and between patients with and...
7.
Carotenuto A, Di Monaco C, Papetti L, Borriello G, Signoriello E, Masciulli C, et al.
J Neurol
. 2024 Aug;
271(10):6773-6781.
PMID: 39177751
Background: Pediatric-onset Multiple Sclerosis (POMS) patients show more inflammatory disease compared with adult-onset MS. However, highly effective treatments are limited with only fingolimod being approved in Italy and natalizumab prescribed...
8.
Petracca M, Petsas N, Sellitto G, Ruotolo I, Livi C, Bonanno V, et al.
Front Neurol
. 2024 Aug;
15:1394867.
PMID: 39175758
Background: Telerehabilitation (TR) offers a valuable opportunity to improve access to care and has shown results comparable to onsite rehabilitation (SR) across different conditions. The present study aimed to explore...
9.
Leodori G, Mancuso M, Maccarrone D, Tartaglia M, Ianniello A, Certo F, et al.
Sci Rep
. 2024 Jul;
14(1):17654.
PMID: 39085330
Motor fatigue in Multiple Sclerosis (MS) is due to reduced motor cortex (M1) output and altered sensorimotor network (SMN) modulation. Natalizumab, a disease-modifying therapy, reduces neuroinflammation and improves fatigue. However,...
10.
Nistri R, Ianniello A, Pozzilli V, Gianni C, Pozzilli C
Diagnostics (Basel)
. 2024 Jun;
14(11).
PMID: 38893646
Brain and spinal cord imaging plays a pivotal role in aiding clinicians with the diagnosis and monitoring of multiple sclerosis. Nevertheless, the significance of magnetic resonance imaging in MS extends...